Obesity drug distribution and delivery shift
Distribution is reshaping the obesity‑drug market: Amazon added Eli Lilly’s GLP‑1 pill to its offering, pressuring incumbent players, while Novo Nordisk struck a $2.1 billion partnership with Vivtex to pursue oral delivery of biologic candidates. Put simply, access and new delivery formats are now as commercially important as the drugs themselves. (investing.com) (pharmexec.com)
Amazon just turned a weight-loss drug into a same-day delivery product. On April 8, Amazon Pharmacy said it would offer Eli Lilly’s new obesity pill Foundayo through same-day delivery in nearly 3,000 U.S. cities and towns, with expansion to nearly 4,500 by the end of 2026. (businesswire.com) That matters because Foundayo is not a weekly injection. Eli Lilly said on April 9 that Foundayo, the brand name for orforglipron, is the only glucagon-like peptide-1 pill for weight loss that can be taken any time of day without food or water restrictions. (prnewswire.com) Amazon is not just shipping boxes here. Amazon said insured patients can see real-time pricing, manufacturer coupons are applied automatically, commercial coverage can bring the price down to $25 a month, and self-pay pricing is $149 a month. (businesswire.com) Amazon also tied the drug to its clinic network. Customers with a valid prescription can pick up Foundayo within minutes at kiosks inside select One Medical offices after an appointment, instead of waiting for a specialty pharmacy shipment. (finance.yahoo.com) Eli Lilly is pushing the same drug through several lanes at once. Fierce Healthcare reported that Lilly launched Foundayo across the United States through LillyDirect, telehealth providers, pharmacies, and Amazon beginning April 9. (fiercehealthcare.com) Novo Nordisk is responding from the other end of the problem. On February 25, Novo and Vivtex announced a partnership worth up to $2.1 billion to develop oral biologic medicines for obesity, diabetes, and related conditions. (biospace.com) A biologic medicine is a large, fragile drug made from proteins or peptides, which are chains of amino acids that act more like precision tools than simple chemicals. Those drugs usually need injections because the stomach and intestines break them down before enough medicine reaches the bloodstream. (vivtex.com) Vivtex is trying to solve that delivery problem inside the gut. The company said its platform screens conditions in the gastrointestinal tract and designs formulations that help biologic drug candidates survive digestion and get absorbed after swallowing. (vivtex.com) Novo gets the delivery technology, and Vivtex gets the economics of a platform bet. Under the deal, Vivtex licenses selected oral drug-delivery technologies to Novo, while Novo takes global development, manufacturing, regulatory work, and commercialization of any resulting products. (biospace.com) So the obesity-drug race now has two separate tracks. Eli Lilly is using a ready-to-ship pill plus Amazon’s logistics to widen access now, while Novo Nordisk is paying for a chance to turn harder-to-swallow biologic candidates into future pills instead of shots. (businesswire.com) (biospace.com)
